Ozanimod

🧮 Dose calculator

Multiple sclerosis (relapsing) · Regimen source: FDA Zeposia · 2.2

• • Days 1–4: 0.23 mg; days 5–7: 0.46 mg. Mild/moderate hepatic impairment: 0.92 mg every other day. Missed dose in the first 2 weeks: restart titration. FDA Zeposia · 2.2, Table 1FDA Zeposia · 2.3FDA Zeposia · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Zeposia · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of ZEPOSIA in pregnant women .”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Zeposia · 8.2

  “Risk Summary There are no data on the presence of ozanimod in human milk, the effects on the breastfed infant, or the effects of the drug on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Zeposia · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Zeposia · 8.5

  “Monitor elderly patients for cardiac and hepatic adverse reactions, because of the greater frequency of reduced cardiac and hepatic function in the elderly population.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Zeposia · 8.3

  “Contraception Before initiation of ZEPOSIA treatment, women of childbearing potential should be counseled on the potential for a serious risk to the fetus and the need for contraception during treatment with ZEPOSIA [see Use in Specific Populations (8.1) ] .”